Citations (24)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Jessica R Thorpe, Rachel A Wilson, Sam Mesiano & Charles J Malemud. (2022) Tofacitinib Inhibits STAT Phosphorylation and Matrix Metalloproteinase-3, -9 and -13 Production by C28/I2 Human Juvenile Chondrocytes. Open Access Rheumatology: Research and Reviews 14, pages 195-209.
Read now
Read now
Chengjuan Chen, Dianxiang Lu, Tao Sun & Tiantai Zhang. (2022) JAK3 inhibitors for the treatment of inflammatory and autoimmune diseases: a patent review (2016–present). Expert Opinion on Therapeutic Patents 32:3, pages 225-242.
Read now
Read now
Karima Alim, Arnaud Bruyère, Alain Lescoat, Elodie Jouan, Valérie Lecureur, Marc Le Vée & Olivier Fardel. (2021) Interactions of janus kinase inhibitors with drug transporters and consequences for pharmacokinetics and toxicity. Expert Opinion on Drug Metabolism & Toxicology 17:3, pages 259-271.
Read now
Read now
Xingrui He, Xiabin Chen, Hancheng Zhang, Tian Xie & Xiang-Yang Ye. (2019) Selective Tyk2 inhibitors as potential therapeutic agents: a patent review (2015–2018). Expert Opinion on Therapeutic Patents 29:2, pages 137-149.
Read now
Read now
Jason G. Kettle, Annika Åstrand, Matthew Catley, Neil P. Grimster, Magnus Nilsson, Qibin Su & Richard Woessner. (2017) Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2. Expert Opinion on Therapeutic Patents 27:2, pages 145-161.
Read now
Read now
Articles from other publishers (19)
Johan Mattsson, Elisabeth Israelsson, Karin Björhall, Linda Fahlén Yrlid, Kristoffer Thörn, Anna Thorén, Emelie Andersén Toledo, Lisa Jinton, Lisa Öberg, Cecilia Wingren, Sofia Tapani, Sonya G. Jackson, Gabriel Skogberg, Anders J. Lundqvist, Ramon Hendrickx, Anders Cavallin, Torben Österlund, Neil P. Grimster, Magnus Nilsson & Annika Åstrand. (2023) Selective Janus kinase 1 inhibition resolves inflammation and restores hair growth offering a viable treatment option for alopecia areata. Skin Health and Disease 3:3.
Crossref
Crossref
Kuojun Zhang, Ke Ye, He Tang, Zhihao Qi, Tianyu Wang, Jie Mao, Xiangyu Zhang & Sheng Jiang. (2023) Development and Therapeutic Implications of Tyrosine Kinase 2 Inhibitors. Journal of Medicinal Chemistry 66:7, pages 4378-4416.
Crossref
Crossref
Liyun Zhao, Qi Liang, Ye He, Maoyu Liu, Rongsheng Tong, Zhongliang Jiang, Wenjing Wang & Jianyou Shi. (2022) HDAC/JAK dual target inhibitors of cancer-related targets: The success of nonclearable linked pharmacophore mode. Bioorganic Chemistry 129, pages 106181.
Crossref
Crossref
Kamonpan Sanachai, Panupong Mahalapbutr, Kowit Hengphasatporn, Yasuteru Shigeta, Supaphorn Seetaha, Lueacha Tabtimmai, Thierry Langer, Peter Wolschann, Tanakorn Kittikool, Sirilata Yotphan, Kiattawee Choowongkomon & Thanyada Rungrotmongkol. (2022) Pharmacophore-Based Virtual Screening and Experimental Validation of Pyrazolone-Derived Inhibitors toward Janus Kinases. ACS Omega 7:37, pages 33548-33559.
Crossref
Crossref
Bharath Kumar Gajjela & Ming-Ming Zhou. (2022) Calming the cytokine storm of COVID-19 through inhibition of JAK2/STAT3 signaling. Drug Discovery Today 27:2, pages 390-400.
Crossref
Crossref
Chenyang Li, Xun Sun, Kun Zhao, Fanxiang Meng, Lin Li, Zhenzhen Mu & Xiuping Han. (2022) Efficacy and Safety of Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis: A Systematic Review and Meta-Analysis. Dermatology 238:4, pages 725-735.
Crossref
Crossref
Jacob M. Rosenberg, Joshua M. Peters, Travis Hughes, Caleb A. Lareau, Leif S. Ludwig, Lucas R. Massoth, Christina Austin-Tse, Heidi L. Rehm, Bryan Bryson, Yi-Bin Chen, Aviv Regev, Alex K. Shalek, Sarah M. Fortune & David B. Sykes. (2022) JAK inhibition in a patient with a STAT1 gain-of-function variant reveals STAT1 dysregulation as a common feature of aplastic anemia. Med 3:1, pages 42-57.e5.
Crossref
Crossref
Ali Berkant Avci, Eugen Feist & Gerd Rüdiger Burmester. (2021) Early phase studies of JAK1 selective inhibitors in rheumatoid arthritis. Rheumatology 60:Supplement_2, pages ii11-ii16.
Crossref
Crossref
Teodora Djikic, Zarko Gagic & Katarina Nikolic. 2021. Molecular Docking for Computer-Aided Drug Design. Molecular Docking for Computer-Aided Drug Design
337
365
.
Safa Daoud & Mutasem O. Taha. (2020) Pharmacophore modeling of JAK1: A target infested with activity-cliffs. Journal of Molecular Graphics and Modelling 99, pages 107615.
Crossref
Crossref
Alain Lescoat, Marie Lelong, Mohamed Jeljeli, Claire Piquet-Pellorce, Claudie Morzadec, Alice Ballerie, Stéphane Jouneau, Patrick Jego, Laurent Vernhet, Fréderic Batteux, Olivier Fardel & Valérie Lecureur. (2020) Combined anti-fibrotic and anti-inflammatory properties of JAK-inhibitors on macrophages in vitro and in vivo: Perspectives for scleroderma-associated interstitial lung disease. Biochemical Pharmacology 178, pages 114103.
Crossref
Crossref
Qibin Su, Erica Banks, Geraldine Bebernitz, Kirsten Bell, Cassandra F. Borenstein, Huawei Chen, Claudio E. Chuaqui, Nanhua Deng, Andrew D. Ferguson, Sameer Kawatkar, Neil P. Grimster, Linette Ruston, Paul D. Lyne, Jon A. ReadXianyou Peng, Xiaohui Pei, Stephen Fawell, Zhanlei Tang, Scott Throner, Melissa M. Vasbinder, Haoyu Wang, Jon Winter-HoltRichard Woessner, Allan Wu, Wenzhan Yang, Michael Zinda & Jason G. Kettle. (2020)
Discovery of (2
R
)-
N
-[3-[2-[(3-Methoxy-1-methyl-pyrazol-4-yl)amino]pyrimidin-4-yl]-1
H
-indol-7-yl]-2-(4-methylpiperazin-1-yl)propenamide (AZD4205) as a Potent and Selective Janus Kinase 1 Inhibitor
. Journal of Medicinal Chemistry 63:9, pages 4517-4527.
Crossref
Crossref
José Antonio Encinar & Javier A. Menendez. (2020) Potential Drugs Targeting Early Innate Immune Evasion of SARS-Coronavirus 2 via 2’-O-Methylation of Viral RNA. Viruses 12:5, pages 525.
Crossref
Crossref
Elham Y. Al-Barghouthy, Areej Abuhammad & Mutasem O. Taha. (2019) QSAR-guided pharmacophore modeling and subsequent virtual screening identify novel TYK2 inhibitor. Medicinal Chemistry Research 28:9, pages 1368-1387.
Crossref
Crossref
Anniina T. Virtanen, Teemu Haikarainen, Juuli Raivola & Olli Silvennoinen. (2019) Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases. BioDrugs 33:1, pages 15-32.
Crossref
Crossref
Hart S. Dengler, Xiumin WuIvan PengCornelia H. Rinderknecht, Youngsu KwonEric Suto, Pawan Bir KohliMarya LiimattaKathy BarrettJulia Lloyd, Gary CainMike Briggs, Stephanie AddoGary SalmonSavita Ubhayakar, Gauri Deshmukh, Sheerin K. Shahidi-Latham, Cristine M. Quiason-Huynh, Janet JackmanJohn LiuNicholas C. Ray, Simon C. Goodacre, Adam Johnson, Brent S. McKenzieWyne P. LeeMark ZakJane R. KennyNico Ghilardi. (2018) Lung-restricted inhibition of Janus kinase 1 is effective in rodent models of asthma. Science Translational Medicine 10:468.
Crossref
Crossref
Neil P. Grimster, Erica Anderson, Marat Alimzhanov, Geraldine Bebernitz, Kirsten Bell, Claudio Chuaqui, Tracy Deegan, Andrew D. Ferguson, Thomas Gero, Andreas Harsch, Dennis Huszar, Aarti Kawatkar, Jason G. Kettle, Paul Lyne, Jon A. Read, Caroline Rivard Costa, Linette Ruston, Patricia Schroeder, Jie Shi, Qibin Su, Scott Throner, Dorin Toader, Melissa Vasbinder, Richard Woessner, Haixia Wang, Allan Wu, Minwei Ye, Weijia Zheng & Michael Zinda. (2018) Discovery and Optimization of a Novel Series of Highly Selective JAK1 Kinase Inhibitors. Journal of Medicinal Chemistry 61:12, pages 5235-5244.
Crossref
Crossref
Daniella M. Schwartz, Yuka Kanno, Alejandro Villarino, Michael Ward, Massimo Gadina & John J. O'Shea. (2017) JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nature Reviews Drug Discovery 16:12, pages 843-862.
Crossref
Crossref
Corinne Miceli-Richard & Maxime Dougados. (2017) Tracking JAKs in spondyloarthritis: rationale and expectations. Annals of the Rheumatic Diseases 76:8, pages 1325-1326.
Crossref
Crossref